Cochrane · systematic review · CD011301
Botulinum toxin type A for facial wrinkles
Camargo, CPires, Xia, J, Costa, CS, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
30
current version
GRADE rated
26
No studies
4
Included studies
NR
No studies 4 · 13.3%Ungraded 0 · 0%Very low 2 · 6.7%Low 4 · 13.3%Moderate 17 · 56.7%High 3 · 10%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of Findings Table ‐ OnabotulinumtoxinA 20U compared to placebo in glabellar lines
Population: glabellar lines
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Partcipant assessment of success Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo | RR 19.45 [8.6, 43.99] | 4 studies · 575 participants | Moderate Downgraded: risk of bias, imprecision |
Major adverse events Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo | OR 3.62 [1.5, 8.74] | 8 studies · 1390 participants | Moderate Downgraded: risk of bias, imprecision |
Physician assessment of success Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo | RR 17.1 [10.07, 29.05] | 7 studies · 1339 participants | Moderate Downgraded: risk of bias, imprecision |
Total adverse events Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo | RR 1.14 [0.89, 1.45] | 8 studies · 1388 participants | Low Downgraded: risk of bias, imprecision |
Duration of treatment effect Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo | no estimate extracted | 1 study · 77 participants | Moderate Downgraded: risk of bias, imprecision |
Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to placebo for glabellar lines
Population: glabellar lines
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant assessment of success by analysing scores and scales ‐ 20 weeks (Validated tools, wrinkles and lines at maximum contraction) Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo | RR 5.33 [1.67, 16.99] | 1 study · 300 participants | High |
Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo | RR 3.36 [0.88, 12.87] | 7 studies · 1294 participants | Moderate Downgraded: risk of bias, imprecision |
Physician assessment of success by analysing scores and scales ‐ 4 weeks Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo | RR 15.78 [8.75, 28.45] | 7 studies · 1060 participants | Moderate Downgraded: risk of bias, imprecision |
Total adverse events Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo | RR 1.25 [1.05, 1.49] | 8 studies · 1471 participants | Low Downgraded: risk of bias, imprecision |
Duration of treatment effect Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo | no estimate extracted | 1 study · 100 participants | Moderate Downgraded: risk of bias, imprecision |
Summary of Findings Table ‐ IncobotulinumtoxinA 20U compared to placebo for glabellar lines
Population: glabellar lines
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant assessment of success by analysing scores and scales ‐ 4 weeks Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo | RR 66.57 [13.5, 328.28] | 2 studies · 547 participants | Moderate Downgraded: risk of bias, imprecision |
Major adverse events Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo | no estimate extracted | 2 studies · 547 participants | Moderate Downgraded: risk of bias, imprecision |
Physician assessment of success by analysing scores and scales Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo | RR 134.62 [19.05, 951.45] | 2 studies · 547 participants | Moderate Downgraded: risk of bias, imprecision |
Total adverse events Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo | RR 1.17 [0.9, 1.53] | 2 studies · 547 participants | Low Downgraded: risk of bias, imprecision |
Duration of treatment effect ‐ not measured Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to OnabotulinumtoxinA 20U in glabellar lines
Population: glabellar lines
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant assessment success by analysing scores and scales ‐ 4 weeks Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U | RR 1 [0.92, 1.08] | 1 study · 388 participants | High |
Major adverse events ‐ Any major adverse events (eyelid ptosis, eyelid sensory disorder, s Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U | OR 2.65 [0.77, 9.09] | 1 study · 433 participants | Moderate Downgraded: imprecision |
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U | RR 1.01 [0.95, 1.06] | 1 study · 388 participants | High |
Total adverse events Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U | RR 1.02 [0.67, 1.54] | 2 studies · 492 participants | Moderate Downgraded: imprecision |
Duration of treatment effect ‐ not measured Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ IncobotulinumtoxinA 24U compared to OnabotulinumtoxinA 24U in glabellar lines
Population: glabellar lines
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant assessment of success by analysing scores and scales ‐ not measured Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U | no estimate extracted | NR | No studies |
Major adverse events Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U | OR 0.02 [0, 1.77] | 1 study · 381 participants | Very low Downgraded: risk of bias, imprecision |
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U | RR 1.01 [0.96, 1.05] | 1 study · 381 participants | Low Downgraded: risk of bias, imprecision |
Total adverse events Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U | OR 0.02 [0, 1.77] | 1 study · 381 participants | Very low Downgraded: risk of bias, imprecision |
Duration of treatment effect ‐ not measured Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U | no estimate extracted | NR | No studies |
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U compared to placebo in glabellar lines
Population: glabellar lines
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) Summary of Findings Table ‐ DaxibotulinumtoxinA 40U vs placebo | RR 21.1 [11.31, 39.34] | 2 studies · 683 participants | Moderate Downgraded: risk of bias |
Major adverse events Summary of Findings Table ‐ DaxibotulinumtoxinA 40U vs placebo | no estimate extracted | 2 studies · 716 participants | Moderate Downgraded: risk of bias |
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) Summary of Findings Table ‐ DaxibotulinumtoxinA 40U vs placebo | RR 23.4 [12.56, 43.61] | 2 studies · 683 participants | Moderate Downgraded: risk of bias |
Total adverse events Summary of Findings Table ‐ DaxibotulinumtoxinA 40U vs placebo | RR 2.23 [1.46, 3.4] | 2 studies · 716 participants | Moderate Downgraded: risk of bias |
Duration of treatment effect Summary of Findings Table ‐ DaxibotulinumtoxinA 40U vs placebo | no estimate extracted | 1 study · 74 participants | Moderate Downgraded: risk of bias |